Clinical trials: CNV
Macular Degeneration, Choroidal Neovascularization
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
The study will investigate the safety and feasibility of using the TheraSight(TM) Brachytherapy System for treatment of wet age-related macular degeneration (AMD).
- Trial name
- NCT00100087
- Testing
- Ocular Brachytherapy
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Theragenics Corporation
Polypoidal Choroidal Vasculopathy
Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen
The aim of this study is to compare the outcomes of different treatment methods including photodynamic therapy (PDT), intravitreal ranibizumab injection (IVR) and combination therapy under the "1+PRN" treatment regimen for…
- Trial name
- NCT03459144
- Testing
- verteporfin, verteporfin and ranibizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Age-related Macular Degeneration
Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)
The purpose of the study was to compare 2 treatment regimens for patients suffering from choroidal neovascularisation secondary to age-related macular degeneration (AMD).
- Trial name
- SALUTE (NCT01148511)
- Testing
- Ranibizumab 0.5 mg
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 99 people
- Sponsor
- Novartis Pharmaceuticals
Choroidal Neovascularization, Age Related Macular Degeneration
Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD
The purpose of the study is to detect persisting or early new activity of choroidal neovascularization (CNV) due to age related macular degeneration (AMD) during the first 12 months following the first ranibizumab dose at…
- Trial name
- NCT03393767
- Testing
- Ranibizumab
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Vista Klinik
Exudative Age-related Macular Degeneration
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD).
- Trial name
- Nexus (NCT01414153)
- Testing
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
- Where
- 44 sites in United States
- Volunteers
- 158 people
- Sponsor
- Lpath, Inc.
Age-related Macular Degeneration
Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration
The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration (AMD).
- Trial name
- NCT01835015
- Testing
- CLG561
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).
- Trial name
- NCT04645212
- Testing
- ADVM-022
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Adverum Biotechnologies, Inc.
Age-related Macular Degeneration
Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina.
- Trial name
- NCT00539734
- Testing
- ranibizumab
- Where
- Thailand
- Volunteers
- 25 people
- Sponsor
- Prince of Songkla University
Age-Related Macular Degeneration (AMD)
A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment.
- Trial name
- NCT00354445
- Testing
- pegaptanib sodium (Macugen)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Eyetech Pharmaceuticals
Polypoidal Choroidal Vasculopathy
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
1. Primary objectives a. To evaluate the Effects of intravitreal Bevacizumab on polypoidal choroidal vasculopathy(PCV) 2. Secondary objectives 1. To assess the changes in visual acuity 2.
- Trial name
- NCT00383812
- Testing
- Intravitreal Bevacizumab
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Asan Medical Center
Idiopathic Choroidal Neovascularization
Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients
After myopia, the second etiology of choroidal neovascularization (CNV) in young adults (<50 years old) is idiopathic choroidal neovascularization (ICNV) whose etiology remains unknown.
- Trial name
- INTUITION (NCT02257502)
- Testing
- aflibercept
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Age Related Macular Degeneration
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
This study is an evaluation of the short term effects on CNV perfusion of a same-day administration of photodynamic therapy (PDT) with Visudyne® and an intravitreal injection of Lucentis® (ranibizumab, 0.3 mg).
- Trial name
- NCT00413829
- Testing
- Intravitreal ranibizumab with photodynamic therapy
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Age-related Macular Degeneration
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
- Trial name
- NCT02214628
- Testing
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Where
- 13 sites in United States
- Volunteers
- 101 people
- Sponsor
- Ophthotech Corporation
Retinal Pigment Epithelial Detachment
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.
- Trial name
- NCT00749021
- Testing
- Ranibizumab
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Clement K. Chan
Trisomy 21 and Other Fetal Aneuploidy
Automated Screen for Fetal Aneuploidy
The purpose of this study is to develop and evaluate a blood test and automated microfluidic test platform for the prenatal screening of fetal aneuploidy.
- Trial name
- FAST1 (NCT03635359)
- Testing
- blood test
- Where
- 6 sites in Australia, Belgium and 4 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- BioCeryx
Neovascular Age-related Macular Degeneration
A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD
This study is designed to assess the efficacy and safety of multiple intravitreal injection of KH902 in patients with CNV due to AMD.
- Trial name
- HOPE (NCT01242254)
- Testing
- Intravitreal injection of KH902
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Wet Macular Degeneration
Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
The purpose of this study is to evaluate the effects and safety of ranibizumab therapy combined with TA versus ranibizumab monotherapy in patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- RANTA (NCT02806752)
- Testing
- Triamcinolone Acetonide, Ranibizumab
- Where
- 7 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Aier School of Ophthalmology, Central South University
Macular Degeneration, Retinal Vein Occlusion
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
The use of intravitreal injections of corticosteroid (triamcinolone acetonide) appears to be a promising treatment for a variety of ocular diseases associated with inflammation.
- Conditions
- Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
- Trial name
- NCT00101764
- Testing
- Triamcinolone Acetonide
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Eye Institute (NEI)
Macular Degeneration, Choroidal Neovascularization
Phase II/III Study of Anti-VEGF in Neovascular AMD
The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD
- Trial name
- NCT00021736
- Testing
- EYE001 anti-VEGF aptamer
- Where
- United States
- Volunteers
- 540 people
- Sponsor
- Eyetech Pharmaceuticals
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- NCT03823300
- Testing
- Faricimab, Aflibercept
- Where
- 137 sites in United States, Argentina and 19 more
- Volunteers
- 658 people
- Sponsor
- Hoffmann-La Roche